Fed Regist. 2017 Sep 29;82(188):45436-8.
With the issuance of this final rule, the Drug Enforcement Administration removes the substance naldemedine (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)-2,3,4,4a,5,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide) including its salts from the schedules of the Controlled Substances Act. Prior to the effective date of this rule, naldemedine was a schedule II controlled substance because it can be derived from opium alkaloids. This action removes the regulatory controls and administrative, civil, and criminal sanctions applicable to controlled substances, including those specific to schedule II controlled substances, on persons who handle (manufacture, distribute, reverse distribute, dispense, conduct research, import, export, or conduct chemical analysis) or propose to handle naldemedine.
随着本最终规则的发布,美国缉毒局将纳地美定((4R,4aS,7aR,12bS)-3-(环丙基甲基)-4a,7,9-三羟基-N-(2-(3-苯基-1,2,4-恶二唑-5-基)丙烷-2-基)-2,3,4,4a,5,7a-六氢-1H-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-6-甲酰胺)及其盐类从《管制物质法》的管制物质清单中移除。在本规则生效日期之前,纳地美定是一种II类管制物质,因为它可从鸦片生物碱中提取。此行动取消了对处理(制造、分销、逆向分销、配药、进行研究、进口、出口或进行化学分析)或提议处理纳地美定的人员适用的管制措施以及对管制物质的行政、民事和刑事制裁,包括那些特定于II类管制物质的制裁。